Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 1;4(1):46-53.
doi: 10.1093/ehjcvp/pvx018.

Interleukin-1 blockade for the treatment of pericarditis

Leo F Buckley  1 , Michele M Viscusi  2 , Benjamin W Van Tassell  1 , Antonio Abbate  2
Affiliations
Review

Interleukin-1 blockade for the treatment of pericarditis

Leo F Buckley et al. Eur Heart J Cardiovasc Pharmacother. .

Abstract

Pericarditis is a debilitating condition that results from profound inflammation of the pericardial tissue. Between 10 and 15% of first episodes of acute pericarditis will be followed by several episodes refractory to conventional treatment. Current standard of care for pericarditis treatment includes high-dose non-steroidal anti-inflammatory drugs, colchicine, and systemic corticosteroids, each associated with potentially severe toxicities and nominal efficacy. Interleukin-1 (IL-1), an apical pro-inflammatory cytokine, plays an important role as an autocrine magnifier of systemic inflammation in pericarditis. Interruption of the IL-1 circuit has been shown to have a favourable risk profile in several disease states. In this review, we discuss the growing body of evidence which supports the use of IL-1 blockade in the treatment of recurrent pericarditis as well as provide practical considerations for the use of IL-1 blockade in clinical practice.

Keywords: Anakinra; Human interleukin-1 receptor antagonist; Interleukin-1; Pericarditis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interleukin-1 and the pathophysiology of pericarditis. An injury due to an infectious or non-infectious irritant triggers the formation of the NLRP3 inflammasome. The NLRP3 inflammasone subsequently initiates a local and systemic inflammatory response through activation and release of Interleukin-1.
Figure 2
Figure 2
Efficacy of anakinra for the prevention of relapse in idiopathic recurrent pericarditis: results from the AIRTRIP Clinical Trial.
See this image and copyright information in PMC

References

    1. Imazio M, Gaita F, LeWinter M.. Evaluation and treatment of pericarditis: a systematic review. JAMA 2015;314:1498–1506. - PubMed
    1. Latz E, Xiao TS, Stutz A.. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013;13:397–411. - PMC - PubMed
    1. Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A.. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal 2015;22:1146–1161. - PubMed
    1. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720–3733. - PMC - PubMed
    1. Mertens M, Singh JA.. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;CD005121. - PubMed

MeSH terms

Substances